GB-0998
- Generic Name
- GB-0998
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 21
- Registration Number
- NCT02342184
- Locations
- 🇯🇵
Department of Neurology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 99
- Registration Number
- NCT02184741
- Locations
- 🇯🇵
Japan Blood Products Organization, Tokyo, Japan
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 17
- Registration Number
- NCT02032095
- Locations
- 🇯🇵
Japan Blood Products Organization, Tokyo, Japan
Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
Phase 3
Completed
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: Placebo of GB-0998
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 26
- Registration Number
- NCT00335985
- Locations
- 🇯🇵
Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath